<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7498411\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="still no approved drug or vaccine that can treat this" exact="disease" post="[3]. Likewise, there are over 200 other infectious diseases"/>
  <result pre="treat this disease [3]. Likewise, there are over 200 other" exact="infectious diseases" post="[2]. In the last two decades, there have been"/>
  <result pre="and socioeconomic losses (Fig. 1 a). For instance, the severe" exact="acute" post="respiratory syndrome (SARS) outbreak in 2003 induced 774 deaths"/>
  <result pre="socioeconomic losses (Fig. 1 a). For instance, the severe acute" exact="respiratory" post="syndrome (SARS) outbreak in 2003 induced 774 deaths and"/>
  <result pre="losses (Fig. 1 a). For instance, the severe acute respiratory" exact="syndrome" post="(SARS) outbreak in 2003 induced 774 deaths and 8096"/>
  <result pre="syndrome (SARS) outbreak in 2003 induced 774 deaths and 8096" exact="infection" post="cases [4], and its economic cost was estimated to"/>
  <result pre="Similarly, approximately 37.9 million people worldwide suffered from the human" exact="immunodeficiency" post="virus (HIV) around the end of 2018 [6], leading"/>
  <result pre="last two decades. HIV: https://www.who.int/hiv/mediacentre/events/en/. SARS: https://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/. Hemagglutinin type1 neuraminidase" exact="type 1" post="(H1N1): https://www.who.int/csr/don/2009_12_30/en/. Middle East respiratory syndrome (MERS): https://www.who.int/emergencies/mers-cov/en/. Zika"/>
  <result pre="https://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/. Hemagglutinin type1 neuraminidase type 1 (H1N1): https://www.who.int/csr/don/2009_12_30/en/. Middle East" exact="respiratory" post="syndrome (MERS): https://www.who.int/emergencies/mers-cov/en/. Zika virus (ZIKV): https://www.who.int/en/news-room/fact-sheets/detail/zika-virus HCV: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c."/>
  <result pre="Hemagglutinin type1 neuraminidase type 1 (H1N1): https://www.who.int/csr/don/2009_12_30/en/. Middle East respiratory" exact="syndrome" post="(MERS): https://www.who.int/emergencies/mers-cov/en/. Zika virus (ZIKV): https://www.who.int/en/news-room/fact-sheets/detail/zika-virus HCV: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Ebola:"/>
  <result pre="peptides, interferon, and oligonucleotide-based therapies can be used to combat" exact="viral" post="infections such as the application of a SARS vaccine"/>
  <result pre="interferon, and oligonucleotide-based therapies can be used to combat viral" exact="infections" post="such as the application of a SARS vaccine or"/>
  <result pre="treatment of 9 types of human transmissible diseases, namely HIV," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), herpesvirus, influenza"/>
  <result pre="of human transmissible diseases, namely HIV, hepatitis B virus (HBV)," exact="hepatitis C" post="virus (HCV), herpesvirus, influenza virus, human cytomegalovirus, varicella-zoster virus,"/>
  <result pre="C virus (HCV), herpesvirus, influenza virus, human cytomegalovirus, varicella-zoster virus," exact="respiratory" post="syncytial virus (RSV), and human papilloma virus (HPV) [2]."/>
  <result pre="human cytomegalovirus, varicella-zoster virus, respiratory syncytial virus (RSV), and human" exact="papilloma" post="virus (HPV) [2]. Although developments of new antiviral drugs,"/>
  <result pre="vaccines, and antibodies are powerful prevention and treatment strategies for" exact="viral" post="infections, most of these selectively target a single virus"/>
  <result pre="most of these selectively target a single virus [9]. Moreover," exact="viral" post="mutation, virus-induced secondary infections, side effects from drugs and"/>
  <result pre="selectively target a single virus [9]. Moreover, viral mutation, virus-induced" exact="secondary" post="infections, side effects from drugs and vaccines, and long"/>
  <result pre="urgent need to realize more effective therapeutic strategies to combat" exact="viral" post="emergence. Nanomaterials present new opportunities for antiviral drug development"/>
  <result pre="side effects on the human body, easily tunable physicochemical properties," exact="lower" post="cost and higher throughput synthesis, etc. These superior properties"/>
  <result pre="[12] 50 nm HBV In vitro Impeding the transcription of" exact="viral" post="RNA by directly binding to HBV DNA. [14] GO"/>
  <result pre="BV, HSV-1 In intro Cationic liposomes with incorporated stearylamine inhibit" exact="viral" post="infectivity. [35] Au NPs 5, 50, 100 nm Thiol"/>
  <result pre="antibody to neutralizing DENV. [38] aDENV: dengue virus; VSV: vesicular" exact="stomatitis" post="virus; BV: baculovirus; ED III: domain III of envelope"/>
  <result pre="COVID-19 [10]. Antiviral nanoagents can be used to disrupt the" exact="viral" post="replication cycle. As shown in Table 1, multifarious nanoagents"/>
  <result pre="shape, and surface) of ENMs facilitate their direct interactions with" exact="viral" post="particles or host cell surface receptors to inhibit virus-cell"/>
  <result pre="Furthermore, our recent study revealed that AgNPs could block the" exact="primary" post="infection of Kaposiâ€™s sarcoma-associated herpesvirus (KSHV) by directly destroying"/>
  <result pre="our recent study revealed that AgNPs could block the primary" exact="infection" post="of Kaposiâ€™s sarcoma-associated herpesvirus (KSHV) by directly destroying its"/>
  <result pre="addition, GO and its derivatives were reported to inhibit virus" exact="infections" post="through competitive binding with the cell receptors [16], or"/>
  <result pre="the cell receptors [16], or inducing conformational damage of the" exact="viral" post="protein [17]. Analogously, by mimicking heparan sulfate proteoglycans on"/>
  <result pre="by mimicking heparan sulfate proteoglycans on the eukaryotic cell surface," exact="viral" post="attachment ligand (VAL)-modified gold nanoparticles (Au NPs) exhibit a"/>
  <result pre="an approved antiviral drug, acyclovir can be used to treat" exact="herpes" post="simplex virus (HSV) infection through disruption of the viral"/>
  <result pre="acyclovir can be used to treat herpes simplex virus (HSV)" exact="infection" post="through disruption of the viral DNA polymerase function by"/>
  <result pre="treat herpes simplex virus (HSV) infection through disruption of the" exact="viral" post="DNA polymerase function by acting as an analog of"/>
  <result pre="2â€²-deoxyaguanosine-5â€²-triphosphate [2]. However, its clinical application is hampered by its" exact="short" post="half-life of less than 3â€¯h and low bioavailability (only"/>
  <result pre="and high negative charge lead to low membrane permeability and" exact="limited" post="cell internalization [22]. However, its encapsulation into cationic liposomal"/>
  <result pre="been reported to result in better inhibition of murine NV" exact="infections" post="[22]. Nanovaccines The biological basis for developing nanovaccines is"/>
  <result pre="to construct nanovaccines for pathogenic viruses. Thus, ENMs loaded with" exact="viral" post="antigens (viral nucleic acids or inactivated proteins) can pre-stimulate"/>
  <result pre="been demonstrated to stimulate the release of proinflammatory factors (i.e.," exact="tumor" post="necrosis factor-Î± (TNF-Î±), interleuin-6 (IL-6), interleuin-2 (IL-2) and granulocyte-macrophage"/>
  <result pre="to achieve antiviral immune responses [25]. Similarly, the loading of" exact="viral" post="DNA or RNA onto ENMs is another effective way"/>
  <result pre="nanovaccines by introducing an eukaryotic expression vector to encode the" exact="viral" post="antigen protein into a host cell to provoke the"/>
  <result pre="a host cell to provoke the immune system into combating" exact="viral" post="infections [26]. Moreover, ENMs can also be used as"/>
  <result pre="host cell to provoke the immune system into combating viral" exact="infections" post="[26]. Moreover, ENMs can also be used as an"/>
  <result pre="ultimately improve antibody levels and immune response to the HCV" exact="infection" post="in immunized mice [27]. Furthermore, nanovaccines based on genetic"/>
  <result pre="bioconjugation, infusion, or mineralization have been successfully applied to treat" exact="infections" post="due to HIV-1, Ebola, and foot-and-mouth disease virus (FMDV)"/>
  <result pre="applied to treat infections due to HIV-1, Ebola, and foot-and-mouth" exact="disease" post="virus (FMDV) [28]. Challenges and knowledge gaps The COVID-19"/>
  <result pre="antiviral nanoagents as a reserve strategy in the fight against" exact="viral" post="epidemics. Research thus far has mostly focused only on"/>
  <result pre="and vaccines, or reusing approved antiviral drugs [3], while the" exact="absence of" post="antiviral nanoagents during this emergency is conspicuous. Moreover, despite"/>
  <result pre="promising versatility of ENMs in antiviral applications, practical therapeutics are" exact="limited" post="in terms of the development of new strategies and"/>
  <result pre="(e.g., ferrets, macaques, and other primates) that better mimic human" exact="disease" post="response must be performed to assess the health risks"/>
  <result pre="activity than current approved antiviral drugs. (ii)Compared to bacteria, virus" exact="infections" post="are more complicated, involving faster transmission and a variable"/>
  <result pre="and COVID-19 belong to the coronavirus family, they exhibit different" exact="infectious" post="and pathogenic effects on patients [29]. Therefore, the design"/>
  <result pre="Therefore, the design of novel antiviral nanoagents for a severe" exact="viral" post="pandemic requires not only specific and broad-spectrum activities of"/>
  <result pre="of antiviral nanoagents, but also a better understanding of the" exact="infection" post="mechanisms, especially for viruses exhibiting a high mutation rate"/>
  <result pre="treatments [30]. (iii)The envelope, capsid, and nucleic acids are the" exact="primary" post="targets in the design of antiviral nanoagents. However, the"/>
  <result pre="which hampers a deeper understanding of the mechanisms that inhibit" exact="virus infection." post="Therefore, the possible interaction mechanisms, including the damage caused"/>
  <result pre="activation of innate and adaptive immunity, should be clarified. (iv)A" exact="viral infection" post="involves the following stages: attachment to membrane receptors, penetration"/>
  <result pre="of innate and adaptive immunity, should be clarified. (iv)A viral" exact="infection" post="involves the following stages: attachment to membrane receptors, penetration"/>
  <result pre="screening of the interactions between ENMs and viruses during the" exact="infection" post="process requires more powerful and high-throughput analytical platforms. (v)The"/>
  <result pre="to the well-balanced dose administration. In addition, the reasons for" exact="secondary" post="adverse outcomes remain unclear, which can be caused by"/>
  <result pre="nonspecific immune response or virus-incurred inflammation during treatment. Therefore, besides" exact="virus infection," post="the immune activation associated with the type and dosage"/>
  <result pre="the most commonly used clinical route, especially for treating an" exact="infection" post="due to influenza virus. However, for gastrointestinal infections caused"/>
  <result pre="treating an infection due to influenza virus. However, for gastrointestinal" exact="infections" post="caused by rotavirus or hepatitis virus, oral administration is"/>
  <result pre="influenza virus. However, for gastrointestinal infections caused by rotavirus or" exact="hepatitis" post="virus, oral administration is better, while intranodal administration may"/>
  <result pre="is better, while intranodal administration may be better for treating" exact="infections" post="caused by respiratory viruses such as SARS and COVID-19."/>
  <result pre="intranodal administration may be better for treating infections caused by" exact="respiratory" post="viruses such as SARS and COVID-19. Therefore, the stability"/>
  <result pre="and highly desirable precaution against the emergence and recurrence of" exact="viral" post="outbreaks. Compared with state-of-the-art approaches such as interfering RNAs,"/>
  <result pre="The authors report no declarations of interest. References References 1Coronavirus" exact="disease" post="(COVID-2019) situation reports, WHO, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. 2De ClercqE.LiG.Clin. Microbiol. Rev.29201669574727281742"/>
  <result pre="July 2003, https://www.who.int/csr/sars/country/table2004_04_21/en/. 5KnoblerS.Learning From SARS: Preparing for the Next" exact="Disease" post="Outbreak: Workshop Summary2004National Academies PressWashington, DC 6World Health OrganizationSummary"/>
  <result pre="- Two-dimensional nanoparticles for the delivery of anticancer drugs and" exact="cancer" post="therapyParakW.J.FeliuN.Frontiers of Nanoscience2020Elsevier151199 33PalmieriV.PapiM.Nano Today332020100883 34JoungY.K.SonS.JangJ.Y.KwonM.H.ParkK.D.Pharm. Res.29201293294222139535 35TaharaK.KobayashiM.YoshidaS.OnoderaR.InoueN.TakeuchiH.Int. J."/>
 </snippets>
</snippetsTree>
